Generics 29

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Imatinib manufacturers

29 products found

Filters

Filters

Filters , active

Country of origin : India

Clear all

29 products found

imatinib

Tablets, film coated 100 mg, 400 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Costa Rica
Registered in
Ireland , Latvia , Lithuania , Malta , Netherlands , Slovenia
Manufacturer #1338

Manufacturer usually replies in 7 days

imatinib

Tablets, film coated 100 mg, 400 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Unavailable markets
Chile , Turkey , Vietnam , Panama , Mexico , Guatemala , Honduras , Nicaragua , El Salvador , Costa Rica , Belize , Haiti , Cuba , Dominican Republic , Jamaica , Bahamas , Barbados , Grenada , Antigua And/Or Barbuda , Dominica , Brazil , Colombia , Argentina
Available for
Licensing with supply
Manufacturer #261
A pharmaceutical manufacturer based in the EU that has been selling its products in Europe for 20+ years. Main therapeutic areas include diabetes, CNL, dermatology, and oncology. Main dosage forms include solid and liquid oral, sterile dosage forms, and ointments. The company possesses 10+ manufacturing facilities that are cGMP-compliant.

Manufacturer usually replies in 6 days

imatinib

Tablets 100 mg, 400 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
India
GMP approvals
EU GMP, ANVISA
Unavailable markets
Vietnam
Manufacturer #9406

Manufacturer usually replies in 8 days

imatinib

Tablets 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #22283

Manufacturer usually replies in 5 days

imatinib

Capsules 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
PICS
Manufacturer #21567

Manufacturer usually replies in 2 days

imatinib

Tablets 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
PICS
Manufacturer #21567

Manufacturer usually replies in 2 days

imatinib

Capsules 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #20510

Manufacturer usually replies in 2 days

imatinib

Tablets 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19664

Manufacturer usually replies in 5 days

imatinib

Capsules 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19664

Manufacturer usually replies in 5 days

imatinib

Capsules 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #18530

Manufacturer usually replies in 4 days

imatinib

Tablets 100 mg, 400 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #17753

Manufacturer usually replies in 10 days

imatinib

Capsules 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #30013

Manufacturer usually replies in 2 days

imatinib

Injection 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #21110

Manufacturer usually replies in 6 days

imatinib

Tablets 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17691

Manufacturer usually replies in 7 days

imatinib

Tablets 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17417

Manufacturer usually replies in 6 days

imatinib

Capsules 100 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17417

Manufacturer usually replies in 6 days

imatinib

Capsules 100mg, 400mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #17147

Manufacturer usually replies in 7 days

imatinib

Tablets 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO, EU GMP
Manufacturer #20273

Manufacturer usually replies in 21 days

imatinib

Tablets 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19639

Manufacturer usually replies in 12 days

imatinib

Injection 100 mg, 400 mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
WHO
Manufacturer #19051

Manufacturer usually replies in 14 days

Want to view all 29 products? Create your free account today!

Imatinib Manufacturers

IMATINIB Mesylate is used to treat certain types of leukemia, type of cancers that begins in the white blood cells, other cancers, and disorders of the blood cells. IMATINIB is also used to treat certain types of gastrointestinal stromal tumors, a type of tumor that grows in the walls of the digestive passages and may spread to other parts of the body. IMATINIB is also used to treat tumors that form under the top layer of skin, especially when the tumor cannot be removed surgically, has spread to other parts of the body, or has come back after surgery. IMATINIB is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells. IMATINIB is sold under the brand name Gleevec among others. Scientists at Ciba-Geigy (which merged with Sandoz in 1996 to become Novartis) invented IMATINIB in the late 1990s, in a team led by biochemist Nicholas Lydon and that included Elisabeth Buchdunger and Jürg Zimmermann. Warnings: Follow all Instructions on your medicine package and label. It is wise to tell your healthcare providers about all your medical allergies, illnesses, and all medicines you use. Before taking IMATINIB: You should not use This medical drug if you are allergic to it This drug may also be used for purposes that may not have been listed in this medication guide. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified rosiglitazone manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.

How does Imatinib work?

The usage of this pharmaceutical substance: Read the Guide and, if available, the Patient Information Leaflet that will be provided by your pharmacist before you start taking IMATINIB. If you have any questions related to this medical remedy, ask your pharmacist or doctor. IMATINIB is a cancer growth blocker called a tyrosine kinase inhibitor. These inhibitors are proteins that cells use to signal to each other to grow. There are a number of different tyrosine kinases and blocking them stops the cancer cells from growing. IMATINIB targets different tyrosine kinases, depending on the type of cancer. It is sold in the tablet form in 100mg, 400mg strengths, in the treatment of Acute Lymphoblastic Leukaemia, the Indicated dosage for adults is 600 mg per day. In the treatment of Myelodysplastic/Myeloproliferative Diseases, the standard adult dose is 400 mg. in the treatment of Chronic Eosinophilic Leukemia, 100 mg which may increase to 400 mg. for treating Mastocytosis, the Indicated dosage for adults with aggressive systemic mastocytosis is 400 mg PO a day and for Gastrointestinal Stromal Tumors, 400 mg

The Cost of Imatinib

An online search for the wholesale price for sale of Imatinib for distributors will reveal a wide range of costs. It will vary from store to store depending on your visit and the country of the wholesale market. The wholesale cost in the developing world is about US$1,386.49–19,162.50 a year. Whereas In the United States a typical dose for a year has a wholesale cost of $84,408, while in the United Kingdom the NHS was paying about £20,980 ($27,973) in 2016. Prices for a 100 mg pill of Gleevec internationally range from $20 to $30, although generic IMATINIB is cheaper, as low as $2 per pill.

Navigating our pharmaceutical marketplace

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Imatinib distributors offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for these substance manufacturers and this substance Imatinib suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Imatinib. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Imatinib is already registered in. Manufacturers also have special, and delivery terms.

Establishing commercial ties

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical product deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers Imatinib suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

Quality Assurance

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen Imatinib Manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.